Nanotechnology: the future of

Parkinson’s treatment?
T Pharmaceutical, introduces Flavisome as an innovative means of combating
early Parkinson’s Disease.

Until now, around 31% of deaths due to neurological conditions have been due to Parkinson’s
disease, but the novel drug Flavisome by T Pharmaceutical is set to change that. Flavisome is
set to prevent the deadly neuronal attack seen in the brains of Parkinson’s patients and protect
the neurons from further damage.

T Pharmaceutical proposed the idea of using flavonoids, compounds found naturally in food,
wines and cheeses, as a substance to protect neurons from oxidative stress. The compound
epigallocatechin gallate (or simply EGCG) is found naturally in green tea and has been
proven to provide a plethora of anti-oxidant effects. Flavisome is unique to T Pharmaceutical
because of its elastic liposome nanocapsule coating, which prolongs the half-life of the drug
within the body. Following successful pre-clinical and clinical trials; the business is set to
release their new drug by June 2020.

Flavisome is set to halt neurodegeneration in the substantia nigra pars compacta. The
nanocapsule ensures that the drug is able to get from the oral intake right through to the
blood-brain barrier without modification, while the elastic liposome protects until it is within
the brain, where the highly lipid structure will then allow the EGCG to work at the pars
compacta. It will be produced using thin-film formation and emulsification-diffusion
technique which are further described in our business plan.

In the pre-clinical trials; T Pharmaceutical proved the capability of this novel drug in its
ability to halt neuronal death, as well as its ability to get to the area of treatment at a fairly
high bioavailability. T Pharmaceutical decided the dosage will be 800mg/day for those in the
early stages of their Parkinson’s Disease. This dose has been determined as a non-toxic dose
for humans through the clinical trials that have been carried out.

The uniqueness of T Pharmaceutical drug lies in the neuroprotective mechanism, and the
modifications carried out to make Flavisome a drug capable of getting an individual patent.
By use of both an elastic liposome and a nanocapsule to protect the EGCG, T Pharmaceutical
has created a drug that is both innovative, made from natural compounds and affordable to
produce.

More information about T Pharmaceutical’s exciting new drug can be found in their business
plan which will be released to the public soon!